

S5 Table. Palliative systemic treatment (yes: n=43, 71.7%, no: n=17, 28.3%)

First line	n=43	Second line	n=32	Third line	n=22	Fourth line	n=15	Fifth line	n=7
2010-2019	20 (46.5)	2010-2019	18 (56.3)	2010-2019	10 (45.5)	2010-2019	8 (53.3)	2010-2019	6 (85.7)
Doxorubicin	1 (2.3)	Docetaxel	3 (9.4%)	Weekly paclitaxel	1 (4.5%)	Docetaxel	1 (6.7%)	Capecitabine	1 (14.3%)
Weekly paclitaxel	1 (2.3)	Capecitabine	2 (6.3)	Capecitabine	2 (9.1)	Gemcitabine	1 (6.7)	Gemcitabine	2 (28.6)
Paclitaxel	1 (2.3)	Gemcitabine	1 (3.2)	Eribulin	2 (9.1)	Vinorelbine	1 (6.7)	CAF/FAC	1 (14.3)
docetaxel	2 (4.7)	Vinorelbine	1 (3.2)	Gemcitabine-vinorelbine	1 (4.5)	Eribulin	1 (6.7)	CMF	1 (14.3)
Capecitabine	6 (14.0)	AC	2 (6.3)	Trastuzumab	1 (4.5)	Gemcitabine-paclitaxel	1 (6.7)	Gemcitabine-vinorelbine	1 (14.3)
AC	1 (2.3)	CMF	1 (3.2)	Capecitabine-lapatinib	1 (4.5)	Capecitabine-lapatinib	2 (13.3)		
CAF/FAC	2 (4.7)	Paclitaxel-carboplatin	1 (3.2)	T-DM1	1 (4.5)	Irinotecan-cisplatin	1 (6.7)		
DA	2 (4.7)	Gemcitabine-cisplatin	1 (3.2)	Irinotecan-capecitabine	1 (4.5)				
DE	1 (2.3)	Trastuzumab	2 (6.5)						
Paclitaxel-carboplatin	1 (2.3)	Capecitabine-lapatinib	1 (3.2)						
Gemcitabine-vinorelbine	1 (2.4)	Paclitaxel-cisplatin	1 (3.2)						
THP	1 (2.4)	Cisplatin	1 (3.2)						
Median PFS (months, range)	5.55 (0.93-20.87)	Median PFS (months, range)	4.08 (0.2-24.67)	Median PFS (months, range)	3.83 (0.67-16.57)	Median PFS (months, range)	4.30 (0.83-15.40)	Median PFS (months, range)	3.90 (0.30-9.83)
2000-2009	18 (41.9)	2000-2009	13 (40.6)	2000-2009	11 (50)	2000-2009	7 (46.7)	2000-2009	1 (14.3)
Weekly paclitaxel	1 (2.4)	Paclitaxel	2 (6.5)	Docetaxel	1 (4.5)	Capecitabine	1 (6.7)	Capecitabine	1 (14.3)
Paclitaxel	2 (4.7)	Docetaxel	3 (9.4)	Capecitabine	1 (4.5)	Gemcitabine	2 (13.3)		
Docetaxel	1 (2.4)	Capecitabine	4 (12.5)	Gemcitabine	2 (9.1)	Vinorelbine	2 (13.3)		
Capecitabine	2 (4.7)	AC	1 (3.2)	AC	1 (4.5)	Gemcitabine-vinorelbine	1 (6.7)		
CAF/FAC	3 (6.8)	Docetaxel-capecitabine	1 (3.2)	DA	1 (4.5)	Etoposide-cisplatin	1 (6.7)		
CMF	1 (2.3)	Gemcitabine-vinorelbine	2 (6.5)	Docetaxel-capecitabine	1 (4.5)				

DA	1 (2.3)			Gemcitabine- cisplatin	1 (4.5)		
Docetaxel- capecitabine	2 (4.7)			Gemcitabine- capecitabine	1 (4.5)		
Capecitabine- cisplatin	1 (2.3)			Capecitabine- vinorelbine	1 (4.5)		
Doxorubicin- paclitaxel	1 (2.3)			OLF	1 (4.5)		
Doxifluridine PO	1 (2.3)						
UFT	1 (2.3)						
Not assessed	1 (2.3)						
Median PFS (months, range)	4.92 (0.3- 19.53)	Median PFS (months, range)	3.90 (0.23- 8.53)	Median PFS (months, range)	6.33 (0.67- 17.97)	Median PFS (months, range)	4.23 (0.97- 8.17)
Unknown period	5 (11.6)	Unknown period	1 (3.1)	Unknown period	1 (4.5)		
Capecitabine	2 (4.7)	Docetaxel	1 (3.1)	Gemcitabine	1 (4.5)		
CAF/FAC	1 (2.3)						
Gemcitabine- vinorelbine	1 (2.3)						
Not assessed	1 (2.3)						

Values are presented as number (%). CAF, cyclophosphamide+doxorubicin+5-fluorouracil; CMF, cyclophosphamide+methotrexate+5-fluorouracil; FAC, 5-fluorouracil+doxorubicin+cyclophosphamide; PFS, progression-free survival; PO, per oral; T-DM1, trastuzumab-emtansine; UFT, uracil-tegafur.